Can I Take Vitamin B6 with Egrifta (Tesamorelin)?

What Is Tesamorelin (Egrifta) and Why Does It Matter for Interaction Checks?

Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Injected subcutaneously once daily at 2 mg, it stimulates the pituitary gland to secrete growth hormone, which in turn raises insulin-like growth factor-1 (IGF-1) and reduces visceral adipose tissue in adults living with HIV [1]. The FDA approved the original Egrifta formulation in 2010 and Egrifta SV (a stabilized-vehicle version) in 2019 [2].

Who Receives Tesamorelin?

Patients using Egrifta typically have HIV and are on antiretroviral therapy (ART). Many simultaneously manage multiple supplements and comedications, making interaction screening especially relevant. A 2018 systematic review in JAIDS confirmed that people living with HIV carry a higher baseline burden of peripheral neuropathy, partly driven by older nucleoside reverse-transcriptase inhibitors such as stavudine and didanosine [3].

How Tesamorelin Is Metabolized

Tesamorelin is a peptide. It undergoes proteolytic degradation in plasma and tissues rather than hepatic cytochrome P450 metabolism [1]. Because it bypasses CYP enzymes entirely, the theoretical risk of classical pharmacokinetic drug-supplement interactions is low. Vitamin B6, for its part, acts primarily as an enzyme cofactor in amino acid and neurotransmitter metabolism and does not substantially inhibit or induce CYP450 isoforms at physiological concentrations [4].

What Is Vitamin B6 and What Do People Take It For?

Vitamin B6 is a water-soluble B-vitamin that exists in three interconvertible forms: pyridoxine (the most common supplement form), pyridoxal, and pyridoxamine. The active coenzyme form, pyridoxal-5-phosphate (PLP), supports over 100 enzymatic reactions including transamination, decarboxylation, and glycogenolysis [4].

Common Supplement Doses Versus Dietary Intake

The Recommended Dietary Allowance for adults aged 19 to 50 is 1.3 mg/day, rising to 1.7 mg/day for men and 1.5 mg/day for women over 50 [5]. Many over-the-counter B-complex products contain 25 to 100 mg of pyridoxine, and some high-potency formulas contain 200 to 500 mg per capsule, doses that far exceed physiological needs and that carry measurable toxicity risk [5].

Why People on Tesamorelin Might Take B6

Several scenarios commonly drive B6 use in this patient population. Some patients take it as part of a general multivitamin or B-complex. Others are prescribed high-dose B6 specifically to prevent pyridoxine-deficiency neuropathy caused by isoniazid (used for tuberculosis prophylaxis in HIV). Still others self-initiate it for nausea, PMS, or general wellness without disclosing it to their prescriber.

Is There a Direct Pharmacokinetic Interaction Between Tesamorelin and Vitamin B6?

No published pharmacokinetic study has documented a direct interaction between tesamorelin and vitamin B6. The Egrifta SV full prescribing information does not list pyridoxine, pyridoxal, or any B-vitamin as a contraindicated or interacting agent [2]. A search of the FDA Adverse Event Reporting System (FAERS) accessible via the FDA's MedWatch database similarly yields no signal for this specific combination [6].

Why No PK Interaction Is Expected

Tesamorelin is cleaved rapidly by dipeptidyl peptidase-IV (DPP-IV) in plasma; modified tesamorelin analogs with a trans-3-hexenoic acid group at the N-terminus partially resist this cleavage, extending half-life to approximately 26 to 28 minutes [1]. Vitamin B6 metabolites are renally excreted after hepatic phosphorylation and oxidation. The two agents share no common transport proteins, plasma protein binding sites, or enzymatic pathways that published pharmacology literature identifies as clinically meaningful overlap [4].

The Real Concern: Overlapping Pharmacodynamic Risks for Peripheral Neuropathy

This is the area where clinical attention is warranted. Both high-dose vitamin B6 and several conditions associated with HIV treatment independently affect peripheral nerve function. The concern is not that the two substances react chemically, but that high-dose B6 can produce or worsen the very neurological symptoms that clinicians and patients need to monitor carefully in the HIV/lipodystrophy population.

High-Dose Vitamin B6 and Sensory Neuropathy

Sustained pyridoxine intake above 100 to 200 mg/day causes a dose-dependent sensory neuropathy. The FDA-established Tolerable Upper Intake Level (UL) for vitamin B6 is 100 mg/day in adults [5]. A landmark 1987 study by Schaumburg et al. Documented sensory neuropathy in all seven patients taking 2,000 mg/day and in some patients taking as little as 200 mg/day for two or more months [7]. A 2023 systematic review in Nutrients (N=172 cases) confirmed that sensory neuropathy occurred at mean supplemental doses of 236 mg/day over a median of 9 months, with symptoms beginning in the hands and feet and sometimes taking months to partially resolve after stopping the supplement [8].

HIV-Associated Peripheral Neuropathy as a Complicating Baseline

An estimated 30 to 60% of people living with HIV develop some form of peripheral neuropathy over their lifetime, according to a pooled analysis published in PLOS ONE [9]. Older antiretrovirals, particularly stavudine (d4T) and didanosine (ddI), are toxic to dorsal root ganglia and remain in use in low-income settings [3]. Even with modern ART, HIV itself drives distal sensory polyneuropathy through immune activation and direct neuronal injury [9]. Adding a supplement that independently damages peripheral nerves risks masking or compounding this baseline vulnerability, complicating the clinical picture when new or worsening neurological symptoms arise.

A Practical Decision Framework for B6 Dosing in Tesamorelin Patients

The following framework reflects HealthRX clinical team guidance for prescribers and patients:

| B6 Daily Dose | Risk Level | Recommended Action | |---|---|---| | <2 mg (diet only or standard multivitamin) | Minimal | No additional monitoring needed | | 2 to 25 mg (low-dose B-complex) | Low | Disclose to prescriber; standard neurological monitoring | | 25 to 100 mg (moderate supplement) | Low-to-moderate | Prescriber review; document reason; monitor for neuropathy symptoms | | 100 to 200 mg (high-dose supplement or therapeutic prescription) | Moderate | Prescriber must evaluate whether benefit outweighs risk; set a defined duration | | Above 200 mg (megadose) | High | Avoid unless under specialist supervision with structured monitoring |

When High-Dose B6 Is Medically Necessary Alongside Tesamorelin

The clearest clinical scenario is isoniazid prophylaxis. The CDC recommends isoniazid (INH) for latent tuberculosis infection, and INH is a known pyridoxine antagonist that can deplete B6 and precipitate neuropathy, particularly in people who are malnourished or who metabolize INH slowly [10]. In this setting, 25 to 50 mg/day of pyridoxine is the standard protective dose recommended by the CDC and confirmed by WHO guidelines on TB treatment [11]. This dose falls well below the 100 mg/day UL and is generally considered safe [5, 10].

Monitoring Protocol When B6 Is Prescribed Therapeutically

When a patient on tesamorelin requires therapeutic B6 supplementation, the HealthRX medical team recommends:

1. Establish a symptom baseline, document any existing tingling, numbness, burning, or proprioceptive changes before initiating supplemental B6.
2. Use the lowest effective dose, 25 to 50 mg/day covers isoniazid-induced B6 depletion without approaching the 100 mg/day UL.
3. Set a re-evaluation date, reassess B6 necessity at 3-month intervals.
4. Advise patients to report new symptoms promptly, sensory changes beginning in the feet warrant same-week contact with the prescribing clinician.

Tesamorelin's Effect on IGF-1 and Glucose: A Separate Monitoring Layer

Tesamorelin raises IGF-1 concentrations. In the phase 3 LIPO-010 trial (N=412), subcutaneous tesamorelin 2 mg daily reduced visceral adipose tissue by 15.2% vs. 1.5% with placebo at 26 weeks (P<0.0001) and raised mean IGF-1 by approximately 80 mcg/L above baseline [12]. Elevated IGF-1 can promote glucose intolerance; the prescribing information notes that tesamorelin may increase blood glucose and carries a precaution for diabetes [2].

Vitamin B6, at high pharmacological doses, has shown mixed effects on glucose metabolism in observational data. One meta-analysis in Diabetes/Metabolism Research and Reviews (2022, 12 RCTs, N=671) found no statistically significant effect of B6 supplementation on fasting glucose or HbA1c [13]. A subsequent 2023 Cochrane review on B-vitamin supplementation similarly found insufficient evidence for a glycemic effect [14]. For patients on tesamorelin who already need glucose monitoring, high-dose B6 supplements do not appear to add a clinically meaningful glycemic interaction, but the prescribing physician should be informed so monitoring is not diluted by untracked variables.

What Tesamorelin Clinical Trials Tell Us About Supplement Co-Administration

Neither the LIPO-010 trial [12] nor the Egrifta Phase 3 extension study published in AIDS (2012, N=270) specifically evaluated B-vitamin co-administration as a variable [15]. This gap means that absence of documented interaction in trial data reflects the absence of study design capturing it, not confirmed safety. The FDA's prescribing label for Egrifta SV states: "Drug interaction studies have not been conducted with Egrifta SV" for most supplement classes [2]. Patients and prescribers should not interpret this silence as explicit clearance.

What the IGF-1 Axis Means for B-Vitamin Metabolism

Growth hormone and IGF-1 influence protein and amino acid turnover broadly. Some evidence from endocrinology literature suggests that GH excess may alter PLP (active B6) kinetics through increased aminotransferase activity, though this remains a theoretical concern at tesamorelin's therapeutic IGF-1 elevations rather than a documented clinical risk [16]. A 2019 review in Endocrine Reviews noted that the GH/IGF-1 axis modulates multiple cofactor-dependent enzymatic pathways, but stopped short of recommending altered B6 dosing in GH-secretagogue users [17].

How to Disclose Supplements to Your Tesamorelin Prescriber

Patients frequently underreport supplement use. A 2017 survey published in JAMA Internal Medicine found that 69% of adults taking supplements did not report use to their physicians at their most recent visit [18]. For HIV patients on Egrifta, full disclosure is especially important because peripheral neuropathy symptom attribution errors, glucose monitoring inaccuracies from untracked variables, and immune-modulating effects of high-dose micronutrients can complicate clinical decisions.

Bring the supplement bottle to the appointment, or use the NIH Office of Dietary Supplements' online label database at ods.od.nih.gov to print the exact product facts before the visit [19]. The prescriber needs brand name, dose per capsule, and frequency.

Questions to Ask Your Prescriber

• "Is the amount of B6 in my multivitamin safe alongside tesamorelin?"
• "Do I need a baseline nerve conduction test before starting high-dose B6?"
• "What neurological symptoms should prompt me to call you immediately?"
• "Should my IGF-1 and glucose be checked more frequently given the supplements I take?"

Safety Signals to Watch For While Taking Both Agents

Any patient on tesamorelin who also takes vitamin B6 supplements should understand which symptoms warrant urgent contact with their provider.

Neurological Warning Signs

New or worsening tingling or numbness that starts in the feet or toes and moves upward is a classic presentation of sensory peripheral neuropathy, whether from high-dose B6 toxicity or HIV-associated nerve disease [7, 8]. Burning pain, difficulty with balance in dim light (reflecting proprioceptive loss), or weakness in the hands also require evaluation. These symptoms do not necessarily mean B6 is the cause, but they require same-week contact with the prescribing team.

Metabolic Warning Signs

Because tesamorelin raises IGF-1 and may impair glucose tolerance, patients should monitor for symptoms of hyperglycemia: excessive thirst, frequent urination, or blurred vision [2]. High-dose B6 does not appear to worsen these symptoms based on available RCT data [13], but any new metabolic complaint should be reported promptly to allow accurate attribution.

Practical Takeaways for Patients and Prescribers

Vitamin B6 at doses found in standard multivitamins (up to 25 mg/day) poses no identified direct interaction with tesamorelin based on current published pharmacology and the FDA prescribing information [2, 4, 5]. The risk matrix shifts meaningfully above 100 mg/day, where B6's independent neurotoxic potential may cloud the clinical picture in a patient population already at elevated neuropathy risk.

The Egrifta SV prescribing information states: "The safety and efficacy of Egrifta SV in patients with active malignancy, disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or trauma, or in patients taking glucocorticoids" requires caution [2]. While B6 is not in that list, the broader instruction to review all concomitant medications and supplements before prescribing applies fully.

For isoniazid-related B6 supplementation specifically, the CDC Prevention and Control of Tuberculosis guideline recommends 25 to 50 mg/day of pyridoxine to prevent INH-induced neuropathy, a dose that falls within the safe range for tesamorelin co-administration [10]. Patients taking doses above 50 mg/day for any reason should have a documented clinical rationale reviewed by their prescriber at least every 3 months.